U.S. Office of Personnel Management Healthcare and Insurance

# **FEHB Program Carrier Letter Health Maintenance Organizations**

Letter No. 2013-09(a) Date: April 22, 2013

Fee-for-service [n/a] Experience-rated HMO [8] Community-rated HMO [7]

# Subject: 2014 Technical Guidance and Instructions for Preparing HMO Benefit and Service Area Proposals

Enclosed are the technical guidance and instructions for preparing your benefit proposals for the contract term January 1, 2014 through December 31, 2014. Please refer to our annual Call Letter (Carrier Letter 2013-04) dated March 21, 2013for policy guidance. Benefit policies from prior years remain in effect unless otherwise noted. The Guidance and instructions are in three parts:

• Part One: Preparing Your Benefit Proposal

• Part Two: Preparing Service Area Changes

Part Three: Benefits for HMOs

Also, please note we have a new survey tool that asks for short responses on topics discussed in the Call Letter. OPM will use this new survey to gather information, along with the responses you provide in your proposal. A copy of the survey is included for informational purposes only as Attachment IX.

Please note: You will receive an email from your contract specialist with a link(s) that will guide you to the online survey tool. Each contract number will have an individualized link. We ask that you complete the survey online by May 31, 2013.

This year's deadlines are as follows:

- **Due by May 3, 2013:** Please send your community benefit package and non-Federal group benefit package we purchased.
- Due by May 31, 2013: Please send your complete proposal for benefit changes and clarifications
  to your contract specialist on a CD-ROM (or other electronic means) in addition to a hard copy.
  Your proposal should include language describing all proposed brochure changes. Your OPM
  contract specialist will discuss your proposed benefits and finalize negotiations in a close-out
  letter.
- **Due byMay 31, 2013:**Please submit survey information electronically.
- Within five business days following receipt of close-out letter or by date set by your contract specialist: Please send him/her an electronic version of your fully revised 2014 brochure. See Attachment V-Preparing Your 2014 Brochure.

Carriers are strongly encouraged, as always, to follow our guiding principles of affordability and value-based benefit design when preparing proposals. This year you will see an increased focus on quantitative data, which we will use to measure plan performance. For some items, we are asking for historical data to establish a baseline.

Enclosed is a checklist (Attachment X) showing all the information to include with your benefit and rate proposals. Please return a completed checklist with your submission.

We appreciate your continued efforts to timely submit benefit and rate proposals and to produce and distribute brochures. We look forward to working closely with you on these essential activities to ensure a successful Open Season again this year.

Sincerely,

John O'Brien Director Healthcare and Insurance

#### **2014 FEHB Proposal Instructions**

### Part One - Preparing Your Benefit Proposal

#### **Experience-rated Plans**

- Submit a copy of a fully executed employer group contract (i.e., *certificate of coverage*) by May 3, 2013, that non-Federal subscribers purchased in 2013.
- If you have not made changes to the level of coverage we already purchase, then submit a statement to that effect. If you have made changes, submit a copy of the new benefit description as explained in <u>Benefit Changes</u> below. You must file your proposed benefit package and the associated rate with your state, if your state requires a filing.

#### **Community-rated Plans**

We will continue to allow HMOs the opportunity to adjust benefits payment levels in response to local market conditions (as indicated in the *Call Letter for the 2009 contract year*). If you choose to offer an alternate community package, you should clearly state your business case for the offering. We will only accept an alternate community package if it is in the best interest of the Government and FEHB enrollees. You should also identify each of the differences between your current benefit package and the proposed offering, and include the impact on your community-rated price proposal.

The alternate benefit package may include greater cost sharing for enrollees in order to offset premiums.

The alternate benefit package may not exclude benefits that are required of all FEHB plans, and may not exclude state mandated benefits. However, other benefits may be reduced or not covered if there is an impact on premiums.

Proposals for alternative benefit changes that would provide premium offset of only minimal actuarial value will not be considered.

Please consult with your contact in the Office of the Actuaries regarding the alternate community package and refer to the rate instructions.

- Submit a copy of a fully executed community-benefit package by May 3, 2013 (a.k.a. master group contract or subscriber certificate), including riders, co-pays, co-insurance, and deductible amounts that your non-Federal subscribers purchased in 2013. If the community benefit package is different from the FEHB's, also send a current copy of the benefit package that we purchased. Please highlight the difference(s) between the FEHB benefits and the package you based it upon. **Note:** If you offer a "national plan" then you need to send us your community benefit package for each state that you cover.
- Attach all community-based riders (e.g., prescription drugs, durable medical equipment) and other changes to the basic package that show additions or modifications to the FEHB offering. The material must show all proposed benefit changes for FEHB for the 2014 contract term, except for those still under review by your state.

If you have not made changes to the level of coverage we already purchase, thensubmit a statement to that effect. If you have made changes, submit a copy of the new benefits description. If your state requires you to file this documentation, file the benefit package and the associated rate with the state first. We will accept the community-benefit package you project will be sold to the majority of your non-Federal subscribers in 2014.

**Note:** Your FEHB rate must be consistent with the community-benefit package it is based on. Benefit differences must be accounted for in your rate proposal or you may end up with a defective community rate.

#### All HMOs

- 1. Complete Attachment II Benefit Change Worksheet that compares your proposed 2014 benefit package and the 2013 benefit package that we purchased. Include on your chart:
  - A. Differences in co-pays, co-insurance, numbers of coverage days, and coverage levels in the two packages.
  - B. For community-rated plans only, indicate whether you include the costs of the differences within your community-rate or in addition to the community-rate you charge to the other groups that purchase this benefit package, and to the FEHB Program; and the number of subscribers/contract holders who purchased the 2013 package and who are expected to purchase the 2014 package.
  - C. Describe your state's filing process for obtaining approval of benefit packages and changes. Provide a copy of your most recent state submission that applies to the benefit package you sent us and a copy of the state's approval document. We usually accept proposed benefit changes if you submitted the changes to your state prior to May 31, 2013, and you obtain approval and submit approval documentation to us by June 30, 2013. If the state grants approval by default, i.e., it does not object to proposed changes within a certain period after it receives the proposal, please so note. The review period must have elapsed without objection by June 30, 2013.
- 2. We will contact the state about benefits as necessary. Please provide the name and phone number of the state official responsible for reviewing your plan's benefits. If your plan operates in more than one state, provide the information for each state.
- 3. Please highlight and address any state-mandated benefits that you have not specifically addressed in previous negotiations. State-mandated benefits should be reported if finalized by May 1, 2013, or if they were not specifically addressed in previous negotiations.

Please send the following material by May 31, 2013:

Your benefit proposal must be complete. The timeframes for concluding benefit negotiations are firm and we cannot consider late proposals. Your benefit proposal should include:

- A signed contracting official's form (Attachment I)
- A comparison of your 2013 benefit package (adjusted for FEHB benefits) and your 2014 benefit package (see #1 above)
- Benefit package documentation (see **Benefit Changes** below)
- A plain language description of each proposed **change** (Attachment II) and the revised language for your 2014 brochure
- A plain language description of each proposed **clarification** (Attachment III) and the revised language for your 2014 brochure

If you anticipate significant changes to your 2014 benefit package, please discuss them with your OPM Contract Specialist before you prepare your submission.

#### **Benefit Changes**

Your proposal must include a narrative description of each proposed benefit change. Please use Attachment II as a template for submitting benefit changes. You must show all changes, however slight, that result in an increase or decrease in benefits as benefit changes, even if there is no rate change. Also, please answer the following questions in worksheet format for **each** proposed benefit change. Indicate if a particular question does not apply and use a separate page for **each** change you propose. We will return any incorrectly formatted submissions.

#### **Information Required for Proposal:**

- Describe the benefit change completely. Show the proposed brochure language, including the "Changes for 2014" section in "plain language" that is, in the active voice and from the member's perspective. Show clearly how the change will affect members. Be sure to show the complete range of the change. For instance, if you are proposing to add an inpatient hospital copay, indicate whether this change will also apply to in-patient hospitalizations under the emergency benefit. If there are two or more changes to the same benefit, please show each change clearly.
- Describe the reason(s) for the proposed benefit change. Tell us whether this change is part of your proposed benefit package or if the change is one you submitted to the state for approval (include documentation). State how you will introduce the change to other employers (e.g., group renewal date). State the percentage of your contract holders/subscribers that now have this benefit and the percentage you project will have it by January 2014.

- State the actuarial value of the change and whether it represents an increase or decrease in (a) the existing benefit, and (b) your overall benefit package. If it is an increase, describe whether any other benefit offsets your proposal.
- If the change is not part of the proposed benefit package, is the change a rider? If yes,
- Is it a community rider (offered to all employer groups at the same rate)?
- State the percentage of your subscribers/contract holders who now purchase this rider and the percentage you project it will cover by next January 1. What is the maximum percentage of all your subscribers/contract holders you expect to cover by this rider and when will that occur?
- Include the cost impact of this rider as a bi-weekly amount for Self Only and Self and Family on Attachment II of your rate calculation. If there is no cost impact or if the rider involves a cost trade-off with another benefit change, show the trade-off or a cost of zero, respectively, on Attachment II to your rate calculation.
- If the change requires new specialties of providers, furnish an attachment that identifies the new providers and network coverage.

#### **Benefit Clarifications**

**Clarifications are not benefit changes.** Please use Attachment III as a template for submitting clarifications. Clarifications help members understand how a benefit is covered.

#### **Information Required for Proposal:**

- Show the current and proposed language for each proposed clarification and reference all portions of the brochure it affects. **Prepare a separate worksheet for each proposed clarification**. You may combine more than one clarification to the same benefit, but you must present each one clearly on the worksheet. Remember to use plain language.
- Explain the reason for the proposed clarification.

#### **Part Two** – **Preparing Service Area Changes**

Unless you inform us of changes, we expect your current FEHB service area and provider network to be available for the 2014 contract term. We are committed to providing as much choice to our customers as possible. Given consolidations in the managed-care industry, there are geographic areas where our customers have more limited choices than in other areas.

Please consider expanding your FEHB service area to all areas in which you have authority to operate. You must submit in electronic format all ZIP Codes for your existing service area and any new service area expansion that you propose.

We will provide detailed instructions for submitting your ZIP Code files in September. However, please note that we will ask you to provide your ZIP Codes in a comma delimited text file format and we will provide instructions for uploading your files to our secure web portal.

- **Service Area Expansion** You must propose any service area expansion by May 31, 2013. We may grant an extension for submitting supporting documentation to us until June 30, 2013.
- **Service Area Reduction** Explain and support any proposed reduction to your service area. If this reduction applies only to the Federal group, please explain.

#### **Important Notices**

- The information you provide about your delivery system must be based on <u>executed</u> contracts. We will not accept letters of intent.
- All provider contracts must have "hold harmless" clauses.
- We will assign new codes as necessary. In some cases, rating area or service area changes require a re-enrollment by your FEHB members. We will advise you if this is necessary.

#### **Service Area Expansion Criteria**

We will evaluate your proposal to expand your service area according to these criteria:

- Legal authority to operate
- Reasonable access to providers
- Choice of quality primary and specialty medical care throughout the service area
- Your ability to provide contracted benefits
- Your proposed service area should be geographically contiguous

You must provide the following information:

#### • A description of the proposed expansion area in which you are approved to operate:

Provide the proposed service area expansion by ZIP Code, county, city or town (whichever applies) and provide a map of the old and new service areas. Provide the exact wording of how you will describe the service area change in the brochure.

#### • The authority to operate in proposed area:

Provide a copy of the document that gives you legal authority to operate in the proposed expansion area, and the name and telephone number of the person at the state agency who is familiar with your service area authority.

#### Access to providers:

Provide the number of primary care physicians, specialty physicians (by their specialty), and hospitals in the proposed area with whom you have **executed** contracts. You must update this information by August 31, 2013. The update should reflect any changes (non-renewals, terminations or additions) in the number of executed provider contracts that may have occurred since the date of your initial submission.

#### Service Area Reduction Criteria

We will evaluate your proposal to reduce your service area or enrollment area according to the following criteria:

- We will accept the elimination of the corresponding service area, if you propose to eliminate an entire enrollment area
- Service area reductions should be associated with the following:
  - Significant loss of provider network
  - Poor market growth
  - Reduction applies to other employer groups
  - Reduction may apply to consolidation of two or more rating areas, or splitting rating areas

You must provide the following information:

#### • A description of the proposed reduced service and enrollment area:

Provide the proposed service area reduction by zip code, county, city or town (whichever applies) and provide a map of the old and new services areas. Provide the exact wording of how you will describe the service area change in the brochure.

#### • All state approvals that apply or associated with the revised service area.

We will not accept service area proposals that result in service areas that are not contiguous or consistent with the residency of the federal population or proposals that seek to provide services only to lower cost enrollees.

# Federal Employees Health Benefits Program statement about Service Area Expansion

# (COMPLETE THIS FORM ONLY IF YOU ARE PROPOSING A SERVICE AREA EXPANSION)

We have prepared the attached service area expansion proposal according to the requirements found in the Technical Guidance for 2014 Benefits and Service Area Proposals. Specifically,

- 1. All provider contracts include "hold harmless" provisions.
- 2. All provider contracts are fully executed at the time of this submission. I understand that letters of intent are not considered contracts for purposes of this certification.

Signatur	e of Plan Co	ntracting O	fficial	
T. 41				
Title				

Date

3. All of the information provided is accurate as of the date of this statement.

#### **Part Three – Benefits for HMOs**

The policies established in prior years remain in effect unless we have stated otherwise. You should work closely with your contract specialist to develop a complete benefit package for 2014. For guidance in preparing your proposal for High Deductible Health Plans (HDHP), Health Savings Accounts (HSA), and Health Reimbursement Arrangements (HRA), please refer to *Call Letter* (Carrier Letter 2008-06) dated March 11, 2008. The FEHB policies include the following:

We expect that you cover state-mandated benefits even if your community package does not specifically reference them unless they are specifically prohibited under FEHB.

As stated in the Call Letter, our four primary performance initiatives this year are:

- Improving the delivery of prescription drug benefits;
- Enhancing wellness programs;
- Advancing quality of care; and
- Encouraging Medicare population pilots.

#### I. CALL LETTER INITIATIVES

#### A. Improving the Delivery of Prescription Drug Benefits

#### 1. Prescription Drugs

Our goal is to keep overall pharmacy trend at or below the industry growth rate, which we project to be approximately 8 percent for 2014. Your proposal should describe how your plan will achieve, maintain, and perhaps even exceed this goal. Your proposal should detail how you will accomplish this through pharmacy benefit structure changes, outreach and other strategies.

Information Required:Completed online survey questions. If your trend is expected to be above the 8 percent goal for 2014, complete Attachment VI- Pharmacy, Table 1.

#### 2. Generic Dispensing Rate

Our goal is to have a generic dispensing rate of at least 80 percent for the FEHB Program in 2014. Your proposal should describe how your plan will achieve, maintain, and perhaps even exceed this goal. Your proposal should detail how you will accomplish this throughthe benefits and administrative programs you will utilize to improve, or maintain, your generic dispensing rate.

Information Required:Completed online survey questions. If your generic dispensing rate is less than 80 percent for the FEHB Program as a whole in 2014,completeAttachment VI- Pharmacy, Table 2.

#### 3. Specialty Drug Trend

Given the expansion in the specialty drug market, we are setting an FEHB Program goal of maintaining specialty drug trend costs at 22 percent or less. Your proposal should state what you expect your plan's trend to be in 2014. If yourcost trend is expected to exceed 22 percent you must submit a proposal to address how you will control rising specialty drug costs that considers both benefit and administrative changes, while remaining respectful of member needs. For reference, OPM's list of specialty drugs can be found in Attachment VIII. This specialty drug list is for the calculation of trend only and should not be used for the administration of benefits. We are also interested in proposals that include specialty pharmacies, prior approval, and programs that limit the quantity dispensed on new prescriptions to assess side effects that may impact a patient's ability to continue therapy.

Information Required: Completed online survey questions. If your specialty drug cost trend is above the 22 percent industry specialty drug trend, complete Attachment VI-Pharmacy, Table 3.

#### 4. Prescription Drug Benefit Administration

We encourage efforts to engage enrollees and their providers in meaningful discussions about clinically effective medications that may be offered at relatively low costs. In addition to maximizing the use of generics, there are many drug classes for which therapeutic equivalents or alternatives can be prescribed. Examples include drugs for insomnia, acid reflux, high blood pressure, high cholesterol, and osteoporosis. Your proposal should address benefit designs, utilization management edits, and other implementation strategies that focus on this area. It shouldalso include information on transition of enrollees from one drug to another, utilization management policies and procedures, customer service, education and grandfathering policies.

Carriers should begin adopting a common pharmacy benefit structure utilizing a minimum of four tiers and propose nomenclature to help members understand pharmacy benefits, including key elements such as cost sharing arrangements. Plans must migrate to the following minimum four-tier prescription drug benefit with common definitions no later than 2016: (1) Tier One: Generics; (2) Tier Two: Preferred Brands; (3) Tier Three: Non-preferred Brands; and (4) Tier Four: Specialty Drugs.

Member cost share should increase from Tier One to Tier Three, with special consideration given to the affordability of specialty drugs. A copayment structure that is easy for members to understand serves as an effective incentive to utilize generics and preferred brands. We would like to know if you currently have or are moving to a four-tier benefit structure in your community package or drug rider. We also strongly encourage use of cost effective medication distribution channels, specifically mail order or retail programs that offer 90 day supplies of maintenance medications.

We understand that members can achieve even greater savings on prescription drugs with minimal member disruption through either a narrower pharmacy network or a preferred pharmacy network, and welcome proposals for narrower or preferred pharmacy networks. If you propose such networks, you must include information about how such changes will impact member access to medications and the proposed exception process for consumers.

Information Required: Completed online survey questions.

#### B. Wellness

#### 1. Comprehensive Wellness Programs

We strongly encourage carriers to re-examine the scope of their wellness programs, outreach efforts, and the level of incentives as detailed below. At a minimum, all FEHB Program carriers must offer a Health Risk Assessment (HRA). Also, carriers must include a plan to offer biometric screening (as a component of preventive care) to covered adults, describing the projected population and the costs for implementation. Biometric screening programs are designed to collect specific metrics on the health status of an individual to assist them in achieving or maintaining better health. Carriers should indicate which of the following elements will be included in their FEHB biometric screening benefits:

- Body mass index (BMI);
- Waist circumference;
- Lipid or cholesterol levels;
- Blood pressure;
- Tobacco use testing (cotinine, etc.); and
- Glucose or Hemoglobin A1c measurement

For both HRAs and biometric screenings, carriers must set participation goals and propose relevant incentives. Proposals should also include a process to communicate results to members' primary care physicians, when applicable. We recommend considering specific outreach to senior populations. If you have a biometric screening program that uses other indicators than those listed above, please describe those indicators in your proposal as well.

We continue to encourage you to offer financial incentives to enrollees who (a) complete anHRA or biometric assessment or (b) participate in wellness activities or treatment plans to improve their health status.

Information Required: Completed Attachment II – Provide a benefit change worksheet for biometric screening that will be proposed as a benefit for 2014. Carriers unable to immediately fulfill this requirement must submit a plan for offering biometric screening, describing the projected population, implementation dates, and associated costs. In addition, please complete the online survey questions.

#### 2. Preventive Care

In accordance with the latest United States Preventive Services Task Force (USPSTF) recommendations, available at

http://www.uspreventiveservicestaskforce.org/uspstf11/obeseadult/obesers.pdf, all FEHB Program carriers must cover screening for all adults for obesity and referrals for behavior change interventions for adults with a Body Mass Index (BMI) over 30kg/m² with no cost sharing. Interventions are still subject to applicable member cost sharing. For additional information on the coverage of preventive services, please view the recently published Centers for Medicare and Medicaid Services FAQs available at

http://cciio.cms.gov/resources/factsheets/aca\_implementation\_faqs12.html.

Information Required: Completed online survey questions.

#### 3. Condition Management

In addition to implementing USPSTF guidance on adult obesity prevention, carriers should review and update their criteria for bariatric surgery coverage. A recent review of FEHB carriers reveals that some have very high BMI thresholds or impose waiting periods that are no longer clinically appropriate. Carriers should describe any revised eligibility criteria for bariatric surgery identified in their review. For further guidance, please see the subsequent Carrier Letter that will be released shortly.

Information Required: Completed online survey questions.

#### C. Advancing Quality of Care

We request that carriers consider hospital performance on CMS measures of hospital acquired conditions (available at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired\_Conditions.html) and early elective delivery as important factors in the choice of network facilities. We also encourage carriers to review the American Board of Internal Medicine (ABIM) Foundation's Choosing Wisely Campaign (available at <a href="http://choosingwisely.org/">http://choosingwisely.org/</a>), which highlights commonly overused tests and procedures. Carriers must select at least three tests or procedures that they will evaluate this year as part of their utilization management programs. In your proposal, identify the tests or procedures that you will focus on, 2012 annual cost and utilization data, and describe your plan for intervention, including projected reductions in cost and utilization data as a result. The list of tests and procedures identified in the Choosing Wisely Campaignthat should be used when completing the online survey is available at <a href="http://www.opm.gov/healthcare-insurance/healthcare/carriers/reference/principles/choosing-wisely-campaign.pdf">http://www.opm.gov/healthcare-insurance/healthcare/carriers/reference/principles/choosing-wisely-campaign.pdf</a>.

.

Finally, we encourage carriers to advance the Meaningful Use (<a href="http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Meaningful Use.html">http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Meaningful Use.html</a>) of health information technology by network providers. We are requesting statistics on the percentage of network providers who have achieved Meaningful Use compliance (Stage 1 or beyond).

Information Required: Completed online survey questions. In addition, please address in your proposal the three tests or procedures you will focus on and describe your plan for intervention.

#### D. Medicare Population Pilots

We are encouraging proposals for pilot programs where participating carriers offer a sub-option for Medicare eligible annuitants as an alternate choice. The sub-option may include premium pass-through accounts for plans to use solely to pay some or all of Medicare Part B premiums. Carriers may propose cost sharing for members with Medicare Part B that is sufficient to encourage them to participate in the pilot program. Increased communication and education to enrollees will be important for the success of the pilot programs.

Information Required: Completed online survey. If proposing a benefit change complete Attachment II - Benefit Change Worksheet #1.

#### II. BENEFITS & SERVICES

#### A. New Guidance: Out-of-Pocket Maximums

The U.S. Department of Health and Human Services issued a final rule regarding out-of-pocket (OOP) maximums that applies to all FEHB plans and becomes effective April 26, 2013. The final rule provided that OOP limits up to the health savings account (HSA) OOP limitapply to all FEHB Program plans. The final rule also sets forth the methods for determining whether health plans provide minimum value (MV). The 2013 OOP limits are \$6,250 for self only and \$12,500 for self and family. For additional information on OOP maximums, please view the recently published Centers for Medicare and Medicaid Services FAQs available at http://cciio.cms.gov/resources/factsheets/aca\_implementation\_faqs12.html.

#### **B.** Continued Focus from Previous Years

#### 1. Coverage of Applied Behavior Analysis (ABA)

We encourage plans to offer Applied Behavior Analysis (ABA) for children with autism.

Information Required: Completed online survey. If you are proposing a benefit change, complete Attachment II - Benefit Change Worksheet #1.

#### 2. Affinity Products

We encourage you to add products on the "non-FEHB" page of your plan brochure that may be of interest to members, especially individual policies for domestic partners, as well as for members who may seek additional insurance products, such as short-term disability.

Information Required: Completed online survey questions.

#### 3. Organ/Tissue Transplants

We have updated the guidance on organ/tissue transplants. When you determine that a transplant service is no longer experimental, but is medically accepted, you may begin providing benefits coverage at that time. Carriers are not obligated to wait for the next contract year before they begin providing such benefits. We have updated the following table in Attachment VII:

Table 1– OPM's required list of covered organ/tissue transplants. We have added autologous transplants for aggressive non-Hodgkin's lymphomas (Mantle Cell lymphoma, adult T-cell leukemia/lymphoma, peripheral T-cell lymphomas and aggressive Dendritic Cell neoplasms to Section IV Table 1 Required Coverage).

Information Required: Completed Attachment VII- 2014 Organ/Tissue Transplants and Diagnoses.

#### 4. **Point of Service Product**

We will consider proposals to offer a Point of Service (POS) product under the FEHB Program. Your plan's proposal must demonstrate experience with a private sector employer who has already purchased the POS product.

#### 5. Grandfathered Plans

You will only need to complete the certification for options that you anticipate will remain grandfathered for plan year 2014, based on benefit changes. Please read the certification carefully as it lists specific regulatory requirements that allow a plan to remain grandfathered under the Affordable Care Act.

We will confirm requested grandfather status once final benefits and rates are negotiated.

Note: If one or more of your plan options was grandfathered in 2013, but will no longer meet regulatory requirements for 2014, then all Affordable Care Act requirements for non-grandfathered plans must be met in 2014.

Information Required: Completed Attachment V- Grandfathered Status Certification.

#### 6. <u>Infertility Treatment</u>

We require you to cover diagnosis and treatment of infertility including at least one type of artificial insemination. **This requirement does not include related prescription drugs.** Your brochure language must indicate if you cover or exclude fertility drugs in both the infertility benefit section and the prescription drug benefit section.

#### **Federal Preemption Authority**

The law governing the FEHB Program gives OPM the authority to pre-empt state laws regarding the nature or extent of coverage or benefits, including payments with respect to benefits. We do not pre-empt state laws that increase our enrollees' benefits unless the state mandate conflicts with Federal law, FEHB regulations, or Program-wide policy.

#### Department of Health and Human Services (HHS) Essential Health Benefits

All plans*must* offer certain essential health benefits (EHB) required by the Department of Health and Human Services (HHS), **without limits on time and cost,** except as prescribed in the Public Health Service Act and HHS regulations. Plans must review HHS guidance on EHB and update benefits accordingly. Under the Affordable Care Act (ACA), EHB must include items and services within at least the following ten categories:

- 1. Ambulatory patient services
- 2. Emergency services
- 3. Hospitalization
- 4. Maternity and newborn care

- 5. Mental health and substance use disorder services, including behavioral health treatment
- 6. Prescription drugs
- 7. Rehabilitative and habilitative services and devices
- 8. Laboratory services
- 9. Preventive and wellness services and chronic disease management
- 10. Pediatric services, including oral and vision care

# Attachment I FEHB Carrier Contracting Official

The Office of Personn	el Management (OPM) v	vill not accept any contractual a	ction from
(including the executor		alless it is signed by one of the position accepted by OPM mends or revises it.	
The people named bel	ow have the authority to	sign a contract or otherwise to b	oind the Carrier
for			_(Plan).
Enrollment code (s):_			_
Typed name	Title	Signature	Date
	Ву:	(Signature of contracting of	official) (Date)
	_	(Typed name and title)	
		(Telephone) (FA	X)
		(Email)	

# Attachment II [Insert Health Plan Name]: Benefit Change Worksheet #1 [Insert Subsection Name]

Please complete <u>a separate worksheet</u> for each proposed benefit change. Please refer to Benefit Changes on page 5 to complete the worksheet.

Benefit Change Description	
Applicable options: High Option Standard Option Basic	CDHP
Item	Narrative Description
Current Benefit	
Proposed Benefit	
Proposed Brochure Language	
Reason	
Cost Impact / Actuarial Value	

#### **Additional Questions:**

- I. Actuarial Value:
  - (a) Is the change an increase or decrease in existing benefit package?
  - (b) If an increase, describe whether any other benefit is off-set by your proposal.
- II. Is the benefit change a part of the plan's proposed community benefits package?
  - (a) If yes, when?
  - (a) If approved, when? (attach supporting documentation)
  - (b) How will the change be introduced to other employers?
  - (c) What percentage of the plan subscribers now have this benefit?
  - (d) What percentage of plan subscribers do you project will have this benefit by January 2014?
- III. If change is not part of proposed community benefits package, is the change a rider?
  - (a) If yes, is it a community rider (offered to all employers at the same rate)?
  - (b) What percentage of plan subscribers now have this benefit?
  - (c) What percentage of plan subscribers do you project will have this benefit by January 2014?
  - (d) What is the maximum percentage of all subscribers you expect to be covered by this rider?
  - (e) When will that occur?
- IV. Will this change require new providers?
  - (a) If yes, provide a copy of the directory which includes new providers.

# Attachment III [Insert Health Plan Name]: Benefit Clarification Worksheet #1 [Insert Subsection Name]

Please refer to Benefit Clarifications on page 6 to complete the worksheet.

Please Note: If the benefit clarification equates to a benefit change, you must indicate it as a benefit change on the Benefit Change Worksheet.

Applicable options: High Option			
Current Benefit Language	<b>Proposed Clarification</b>	Reason For Benefit Clarification	

## Attachment IV Preparing Your 2014 Brochure

#### Summary of Plan Benefits

FEHB plans will continue to provide a summary of plan benefits and coverage (SBC) based on standards developed by the Secretary of the Department of Labor. You will receive additional information regarding the SBC in a subsequent carrier letter.

#### Going Green

We appreciate your efforts to support our "Going Green" goals to help reduce FEHB administrative costs. Once again, you must provide paper copies of plan brochures to new members or only upon request to current members and may send Explanations of Benefits, newsletters and other plan materials electronically.

Last year we asked you to estimate savings from your paper reduction initiatives. Please provide responses to the online survey questions that address those savings.

#### Timeline: 2014 Brochure Process

We will continue to use the brochure process we implemented last year. This process is a web application that uses database software to generate a Section 508-compliant PDF. This year's deadlines and significant dates are:

DEADLINES	ACTIVITY
May 31	Plans submit Section 5 Benefits information with proposal if
	suggesting new option
July 2	Plans receive 2014 FEHBBrochure Handbook via listserv
July 2	OPM will provide 2014 Brochure Creation Tool (BCT) User
	Manual
July 10-12 & 15-19	OPM in-house training on the use of the Brochure Creation Tool
July 2-August 31	OPM circulates updated FEHB Brochure Handbook pages by
	listserv
September 4	Plans must enter all data into Section 5 Benefits and update all plan
	specific information in the brochure tool. Plans will be unable to make
	changes after this date so that Contract Specialists can review PDF
	versions of plan brochures. If changes need to be made, we will unlock
	plan brochures on a case-by-case basis.
September 10	OPM sends brochure quantity form to plan after Contract Specialist
	approves brochure for printing as well as other related Open Season
	instructions
August 24	OPM's deadline to finalize all language and shipping labels

In mid-July, we will provide in-house training to refresh plans on the use of the Brochure Creation Tool with 8 individual sessions held at OPM. We will notify plans via the FEHB Carriers listserv about the training dates and times. Please send any comments or questions pertaining to the Brochure Creation Tool to Lionell Jones at lionell.jones@opm.gov or Angelo Cueto at angelo.cueto@opm.gov.

# Attachment V Grandfathered Status Certification

The Patient Protection and Affordable Care Act, as amended ("the Act"), imposes coverage, premium and notification requirements for group health plans. Certain existing group health plans, referred to as "grandfathered plans," are exempt from some of those requirements.

According to regulations published jointly by the Departments of Treasury, Labor and Health and Human Services (<a href="http://cciio.cms.gov/programs/marketreforms/grandfathered/index.html">http://cciio.cms.gov/programs/marketreforms/grandfathered/index.html</a>), health plans existing on March 23, 2010 may meet the definition of a grandfathered health plan by making only certain limited changes to benefits and rates each year and by complying with certain notification and records retention requirements.

The checklist below lists the regulatory requirements. If an FEHB plan chooses to assert grandfathered status for plan year 2014, it must certify that the applicable plan option, based on its proposed benefit changes from 2010 to 2014, meets the definition of a grandfathered plan. (Be aware that a group health plan ceases to be a grandfathered health plan if the employer or employee organization decreases its contribution rate based on cost of coverage towards the cost of any tier of coverage for any class of similarly situated individuals by more than 5 percentage points below the contribution rate for the coverage period that includes March 23, 2010. You are <u>not</u> certifying to this requirement.) If the plan option meets all the requirements listed below, plans should certify that this option is considered grandfathered under the Act, pending final rate determinations.

# You only need to submit this certification if you assert that a particular plan option continues to meet the requirements to remain grandfathered for 2014.

Grandfathered plans should note these record keeping and notification requirements for 2014:

- Include a statement in plan materials describing benefits (plan brochure) that the plan believes it is a grandfathered health plan and include contact information for enrollee complaints. OPM will provide standard plan language for FEHB brochures disclosing a plan's grandfathered status.
- Maintain records documenting terms of the plan in effect on the date the Affordable Care Act was enacted.

## Attachment V Grandfathered Status Certification-Page 2

#### **Plan Name and Option:**

#### **Carrier Codes:**

Category	Requirement (Change from 2010)	Met by 2014 Benefit Package: Yes or No
Benefits	Benefit option has not eliminated all or substantially	
	all benefits to diagnose or treat a particular	
	condition. Plan has not eliminated benefits	
	considered necessary to treat a particular condition.	
Cost Sharing	Benefit option has not made any increase in	
(coinsurance)	percentage cost sharing amount.	
Fixed Cost Sharing	Benefit option has not increased deductibles or out-	
(Deductible or Out-	of-pocket- limits more than medical inflation* plus	
of-Pocket Limit)	15 percentage points.	
Fixed- Amount	Benefit option has not increased copayments more	
Copayment	than the greater of: 1) \$5 increased by medical	
	inflation* (\$5 plus medical inflation times \$5) or 2)	
	medical inflation plus 15 percentage points (by	
	expressing copayment as a percentage).	
Changes in annual	Benefit option has not imposed an overall annual	
limits	limit on the dollar value of all benefits.	

<sup>\*</sup> Medical Inflation means the increase since March 2010 in the overall medical care component of the Consumer Price Index for All Urban Consumers (CPI-U) (unadjusted). Increase is computed by subtracting 387.142 (CPI-U for March 2010) from the indexed amount for any months before the new change is to take effect.

I certify that this plan option meets the requirements of the Patient Protection and Affordable Care Act as a Grandfathered plan (pending final rate determinations.)

#### **Signature of authorized contracting official:**

Name	Date
The state of the s	

#### Title

Please return this page to your OPM Contract Specialist for each grandfathered plan option under the FEHB Program. Your Contract Specialist will provide the deadline to return this certification.

# Attachment VI Pharmacy

# **Table 1: Pharmacy Drug Trend**

Remember to prepare your data worksheet to return to the OPM actuaries.

Our target pharmacy drug trend for 2014 is 8% or below. Is your current pharmacy drug trend at 8% or below? Yes \_\_No\_\_.

<u>If yes</u>, you may skip the rest of this worksheet. <u>If no</u>, please describe what activities, beyond those currently in place, that you will implement to reach this target for 2014? Please describe the three activities that are most likely to help you reach this goal.

Pharmacy Drug Trend Initiative	
Target Beneficiary Population	
Anticipated participation rate	
F	
Expected beneficiary impact	
Projected results: each target population	

Pharmacy Drug Trend Initiative	
Target Beneficiary Population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	
Pharmacy Drug Trend Initiative	
Target Beneficiary Population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	

# Attachment VI Pharmacy

# **Table 2: Generic Dispensing Rate (GDR)**

Remember to prepare your data worksheet to return to the OPM actuaries.

We have a target GDR for 2014 of at least 80%. Is your current GDR at least 80%? Yes \_\_No\_\_.

<u>If yes</u>, you may skip the rest of this worksheet. <u>If no</u>, please describe what activities, beyond those currently in placethat you will implement to reach this target for 2014? Please describe the three activities that are most likely to help you reach this goal.

Generic Initiative	
Target Beneficiary Population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	
Generic Initiative	
Target Beneficiary Population	

Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	
Generic Initiative	
Target Beneficiary Population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	

# Attachment VI Pharmacy

# **Table 3: Specialty**

Remember to prepare your data worksheet to return to the OPM actuaries.

We have a specialty pharmacy trend target for 2014 of keeping cost trends at or below 22 percent. Is your current cost trend at or below 22 percent? Yes\_\_No\_\_.

<u>If yes</u>, you may skip the rest of this worksheet.<u>If no</u>, please describe what activities,beyond those currently in place, that you will implement to reach this target for 2014? Please describe the three activities that are most likely to help you reach this goal.

Specialty Initiative	
Target beneficiary population	
ranger beneficiary population	
Anticipated participation rate	
Expected beneficiary impact	
Projected regults; each target population	
Projected results: each target population	

Specialty Initiative	
-	
Target beneficiary population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	
<b>Specialty Initiative</b>	
Target beneficiary population	
Anticipated participation rate	
Expected beneficiary impact	
Projected results: each target population	
Projected results: each target population	
Projected results: each target population	

# Attachment VII 2014 Organ/Tissue Transplants and Diagnoses

# **Table 1: Required Coverage**

NOTE: \* indicates an addition to the chart for 2014.

I. Solid Organ Transplants: Subject to Medical Necessity	Reference
Cornea	Call Letter 92-09
Heart	Call Letter 92-09
Heart-lung	Call Letter 92-09
Kidney	Call Letter 92-09
Liver	Call Letter 92-09
Pancreas	Call Letter 92-09
Intestinal transplants (small intestine with the liver) or small intestine with multiple organs such as the liver, stomach, and pancreas	Carrier Letter 2001-18
Lung: Single/bilateral/lobar	Carrier Letter 91-08
II. Blood or Marrow Stem Cell Transplants: Not Subject to Medical Necessity. Plan's Denial is Limited to the cytogenetics, subtype or staging of the diagnosis (e.g. acute, chronic) as appropriate for the diagnosis.	
Allogeneic transplants for:	
Acute lymphocytic or non-lymphocytic (i.e., myelogenous) leukemia	
Advanced Hodgkin's lymphoma – relapsed	
Advanced non-Hodgkin's lymphoma - relapsed	
Acute myeloid leukemia	
Advanced Myeloproliferative Disorders (MPDs)	
Amyloidosis	
Chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL)	
Hemoglobinopathy	
Marrow Failure and Related Disorders (i.e., Fanconi's, PNH, Pure Red Cell Aplasia)	
Myelodysplasia/Myelodysplastic Syndromes	
Paroxysmal Nocturnal Hemoglobinuria	
Severe combined immunodeficiency	
Severe or very severe aplastic anemia	
Autologous transplants for:	
Acute lymphocytic or nonlymphocytic (i.e., myelogenous) leukemia	Call Letter 96-08B
Advanced Hodgkin's lymphoma – relapsed	Call Letter 96-08B
Advanced non-Hodgkin's lymphoma - relapsed	Call Letter 96-08B
Amyloidosis	

Neuroblastoma	Call Letter 96-08B
III.Blood or Marrow Stem Cell Transplants: Not Subject to Medical Necessity	
Allogeneic transplants for:	
Phagocytic/Hemophagocytic deficiency diseases (e.g., Wiskott-Aldrich syndrome)	
Autologous transplants for:	
Multiple myeloma	Carrier Letter 94-23, Call Letter 96-08B
Testicular, Mediastinal, Retroperitoneal, and Ovarian germ cell tumors	Carrier Letter 94-23, Call Letter 96-08B
IV. Blood or Marrow Stem Cell Transplants: Not Subject to Medical Necessity. May Be Limited to Clinical Trials.	
Autologous transplants for:	
Epithelial ovarian cancer	Carrier Letter 94-23 Call Letter 96-08B
Childhood rhabdomyosarcoma	
Advanced Ewing sarcoma	
*Aggressive non-Hodgkin's lymphomas (Mantle Cell lymphoma, adult T-cell leukemia/lymphoma, peripheral T-cell lymphomas and aggressive Dendritic Cell neoplasms)	Carrier Letter 2013-12a
Advanced Childhood kidney cancers	
Mantle Cell (Non-Hodgkin lymphoma)	
V. Mini-transplants performed in a Clinical Trial Setting (non-myeloablative, reduced intensity conditioning for member over 60 years of age with a diagnosis listed under Section II): Subject to Medical Necessity	
VI. Tandem transplants: Subject to medical necessity	
Autologous tandem transplants for:	
AL Amyloidosis	
Multiple myeloma (de novo and treated)	
Recurrent germ cell tumors (including testicular cancer)	Call Letter 2002-14

### Table 2: Recommended For Coverage; Transplants under Clinical Trials

Technology and clinical advancements are continually evolving. Plans are encouraged to provide coverage during the contract year for transplant services recommended under Clinical Trials. These types of transplants may transition from experimental/investigational and become consistent with standards of good medical practice in the U.S. for the diagnosed condition. Please return this worksheet with your proposal.

	Does your plan cover this transplant for 2014?	
<b>Blood or Marrow Stem Cell Transplants</b>	Yes	No
Allogeneic transplants for:		
Early stage (indolent or non-advanced) small cell lymphocytic lymphoma		
Multiple myeloma		
Multiple sclerosis		
Sickle Cell		
Beta Thalassemia Major		
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)		
Non-myeloablative allogeneic transplants for:		
Acute lymphocytic or non-lymphocytic (i.e., myelogenous) leukemia		
Advanced Hodgkin's lymphoma		
Advanced non-Hodgkin's lymphoma		
Breast cancer		
Chronic lymphocytic leukemia		
Chronic myelogenous leukemia		
Colon cancer		
Chronic lymphocytic lymphoma/small lymphocytic lymphoma (CLL/SLL)		
Early stage (indolent or non-advanced) small cell lymphocytic lymphoma		
Multiple Myeloma		
Multiple Sclerosis		
Myeloproliferative Disorders		
Myelodysplasia/Myelodysplastic Syndromes		
Non-small cell lung cancer		
Ovarian cancer		
Prostate cancer		
Renal cell carcinoma		
Sarcomas		
Sickle Cell disease		
Autologous transplants for:		
Chronic myelogenous leukemia		
Chronic lymphocytic lymphoma/small lymphocytic lymphoma (CLL/SLL)		
Early stage (indolent or non-advanced) small cell lymphocytic lymphoma		

Small cell lung cancer	
Autologous transplants for the following autoimmune diseases:	
Multiple sclerosis	
Systemic lupus erythematosus	
Systemic sclerosis	
Sclerodema	
Scleroderma-SSc (severe, progressive)	

## Table 3: Recommended For Coverage; Rare Organ/Tissue Transplants

Technology and clinical advancements are continually evolving. Plans are encouraged to provide coverage during the contract year for transplant services that transition from experimental/investigational. These types of transplants may transition from experimental/investigational and become consistent with standards of good medical practice in the U.S. for the diagnosed condition. Please return this worksheet with your proposal.

	Does your plan cover this transplant for 2014?	
Solid Organ Transplants	Yes	No
Autologous pancreas islet cell transplant (as an adjunct to total or near total pancreatectomy) only for patients with chronic pancreatitis		
Blood or Marrow Stem Cell Transplants		
Allogeneic transplants for:		
Advanced neuroblastoma		
Infantile malignant osteopetrosis		
Kostmann's syndrome		
Leukocyte adhesion deficiencies		
Mucolipidosis (e.g., Gaucher's disease, metachromatic leukodystrophy, adrenoleukodystrophy)		
Mucopolysaccharidosis (e.g., Hunter's syndrome, Hurler's syndrome, Sanfilippo's syndrome, Maroteaux-Lamy syndrome variants)		
Myeloproliferative disorders		
Sickle cell anemia		
X-linked lymphoproliferative syndrome		
Autologous transplants for:		
Ependymoblastoma		
Ewing's sarcoma		
Medulloblastoma		
Pineoblastoma		
Waldenstrom'smacroglobulinemia		

# Attachment VIII Specialty Drug List

Examples of Brand Rx
Ziagen
Epzicom
Trizivir
Orencia
Zytiga
Humira
Hepsera
Eylea
Fabrazyme
Amevive
Lumizyme, Myozyme
Aralast, Glassia
Letairis
Kineret
Koate-DVI, Monoclate-P
Hemofil M, Kogenate FS, Recombinatef, HelixateFS
Xyntha, Advate, XynthaSolofuse
Humate-P, Alphanate
Apokyn
Reyataz
Inlyta
Nulojix
Benlysta
Targretin
Victrelis
Tracleer
Dysport, Botox
Myobloc
Berinert, Cinryze
Ilaris
Xeloda
Qutenza
Cimzia
Cetrotide

CHORIONIC GONADOTROPIN COAGULATION FACTOR IX COAGULATION FACTOR IX (HUMAN) Mononine  COAGULATION FACTOR IX (HUMAN) Mononine  COAGULATION FACTOR IX (RECOMBINANT) COAGULATION FACTOR IX (RECOMBINANT) COBCISTAT; ELVITEGRAVIR; TENOFOVIR; EMTRICITABINE COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Xiaflex CYCLOSPORINE Gengraf, Sandimmune, Neoral CYCLOSPORINE CYSTEAMINE CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) DALFAMPRIDINE Ampyra DARREPOETIN ALFA Aranesp DARRINAVIR Prezista DARRINAVIR DEFERASIROX EGARGALIX Firmagon DEFERASIROX EGARGALIX Firmagon DESPEROXAMINE DESPEROXAMINE DESSPEROXAMINE DESPEROXAMINE DESTRANOMER AND SODIUM HYALURONATE DESTRANOMER AND SODIUM HYALURONATE DENANSINE DESTRANOMER AND SODIUM HYALURONATE DENANSINE DENANSINE DESTRANOMER AND SODIUM HYALURONATE DENANSINE DESTRANOMER AND SODIUM HYALURONATE DENANSINE DESTRANOMER DEST	GYODYOLYG GOLYL D OFFI ODDY	
COAGULATION FACTOR IX (HUMAN) COAGULATION FACTOR IX (RECOMBINANT) COAGULATION FACTOR VIIA (RECOMBINANT) COBCUSTAT; ELVITEGRAVIR; TENOFOVIR; EMTRICITABINE COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Xiaflex CRIZOTINIB CYCLOSPORINE Gengraf, Sandimmune, Neoral CYSTEAMINE CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CARLOR Ampyra DALFAMPRIDINE DARBEPOETIN ALFA DASATINIB DEFERASIROX DESARROX		
COAGULATION FACTOR IX (RECOMBINANT) COAGULATION FACTOR VIIA (RECOMBINANT) COBICISTAT; ELVITEGRAVIR; TENOFOVIR; EMTRICITABINE COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Xiaflex CRIZOTINIB CYCLOSPORINE CYCLOSPORINE CYSTEAMINE CYSTEAMINE CYSTEAMINE CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CARRENDINE DALFAMPRIDINE DALFAMPRIDINE DALFAMPRIDINE DARBEPOETIN ALFA Aranesp DARUNAVIR Prezista DASATINIB DEFERASIROX Exjade DEGARELIX Firmagon DEIFERASIROX Firmagon DEIFERASIRON DEIAVIRDINE DENOSUMAB DESFEROXAMINE DESSEROXAMINE DESSEROXAMINE DESSEROXAMINE DESSEROXAMINE DESTERANOME DEXTRANOMER AND SODIUM HYALURONATE SOLESTA DORNASE ALFA PUIMOZYME ECULIZUMAB ESTAVIRENZ EFAVIRENZ SUSTIVA EFAVIRENZ FAVIRENZ FAVIRENZ FAVIRENZ FAVIRENZ EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE ENTELOYOVIR; RILPIVIRINE ENTELOYIR ENZOON		•
COAGULATION FACTOR VIIa (RECOMBINANT)  COBICISTAT; ELVITEGRAVIR; TENOFOVIR; EMTRICITABINE  COLLAGENASE CLOSTRIDIUM HISTOLYTICUM  CRIZOTINIB  CYCLOSPORINE  CYCLOSPORINE  CYSTEAMINE  CYSTEAMINE  CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS  (HUMAN)  CHUMAN)  CYLOGGAM  DALFAMPRIDINE  DARBEPOETIN ALFA  Aranesp  DARUNAVIR  PRESIAB  DARSATINIB  DEFFRASIROX  Esjade  DEFFRASIROX  DELAVIRDINE  DELAVIRDINE  DELAVIRDINE  DELAVIRDINE  DELAVIRDINE  DESFRASIROX  DESFROXAMINE  DELAVIRDINE  DELAVIRDINE  DESFRASIROX  DESFROXAMINE  DESFRASIROX  DESFROXAMINE  DESTRANOMER AND SODIUM HYALURONATE  DEXAMETHASONE  DEXTRANOMER AND SODIUM HYALURONATE  SOLESTA  DIDANOSINE  DORNASE ALFA  Pulmozyme  ECULIZUMAB  EFAVIRENZ  FAVIRENZ  FAVIRENZ  FAVIRENZ  EFAVIRENZ  EFAVIRENZ  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR; EMTRICITABINE  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  COMPLETA  ENTERCAVIR  ENTERCAVIR  ENTERCAVIR  ENTERCAVIR  ENTERCAVIR  ENTERCAVIR  ENTERCITABINE; TENOFOVIR; RILPIVIRINE  ENTERCAVIR  ENTERCITABINE  ENTERCAVIR  ENTERCITABINE  ENTERCAVIR  ENTERCITABINE  ENTERCAVIR  ENTERCEPT  ENDOGESTREL  ETNONGESTREL  ETNONGESTREL  ETNONGESTREL  ETNONGESTREL  ETNONGESTREL  ETNONGESTREL  ETRACOMPLEX  BEbulin, Bebulin VH	` '	
COBICISTAT; ELVITEGRAVIR; TENOFOVIR; EMTRICITABINE COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Xiaflex CRIZOTINIB CRIZOTINIB CYCLOSPORINE Gengraf, Sandimmune, Neoral CYSTEAMINE CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) DALFAMPRIDINE Ampyra AARBEPOETIN ALFA Aranesp DARSATINIB DEFERASIROX Exjade DEGARELIX Firmagon DELAVIRDINE DELAVIRDINE DESPEROXAMINE DESPEROXAMINE DESPEROXAMINE DESPEROXAMINE DESPEROXAMINE DESPEROXAMINE DEXAMETHASONE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE VIdex, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EMTRICITABINE; TENOFOVIR; EMTRICITABINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR ETANENCE ETANECE ETANEC	`	
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM CRIZOTINIB CRIZOTINIB CYCLOSPORINE CYSTEAMINE CYGAGM DALPAMPRIDINE Annpyra Annpyra Annpyra DARBEPOETIN ALFA Aranesp Aranesp DARUNAVIR Prezista DASATINIB Sprycel DEFERASIROX Exjade DEFERASIROX Exjade DEFERASIROX Exjade DEGARELIX Firmagon DENOSUMAB Prolia, Xgeva DESCAMINE DESCAMINE DESCAMINE DESCAMINE DESCAMINE DESCAMINE DESCAMINE DESCAMINE DESCAMINE DIDANOSINE Videx, Videx EC DORNASE ALFA PUMDZYME ECULIZUMAB SOliris EFAVIRENZ EFAVIRENZ EFAVIRENZ, TENOFOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR ENTERCAVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE Complera ENTELOTINIB ENTELOTINIB ENTERCAVIR ENTERCEPT ENDORGESTREL Implanon, Nexplanon ETRACVIRUS FACTOR IX COMPLEX Bebulin, Bebulin VH		
CRIZOTINIB CYCLOSPORINE CYCLOSPORINE CYSTEAMINE CYSTEAMINE CYSTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CARBEPOETIN ALFA DARBEPOETIN ALFA DARBEPOETIN ALFA DASATINIB DEFERASIROX DEGARELIX DELAVIRDINE DELAVIRDINE DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DESFEROXAMINE DESFEROXAMINE DESTERANDONINE DENOSUMAB DESTERANDONINE DENOSUMAB DESTERANDONINE DESTERANDONINE DEXAMETHASONE DORNASE ALFA DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE ENTEROFOVIR; RILPIVIRINE COMPLETE ENTECAVIR ENZEE ENTECAVIR ENTERCAVIR ENZEE ENTECAVIR ENTERCAVIR ENZEE ENTECAVIR ENTERCAVIR ENZEE ENTECAVIR ENZEE	·	
CYSTEAMINE Cystagon CYSTEAMINE Cystagon CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CytoGam DALFAMPRIDINE Ampyra DARBEPOETIN ALFA Aranesp DARUNAVIR DASATINIB Sprycel DEFERASIROX Exjade DEGARELIX Firmagon DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE Desferal DEXAMETHASONE Ozurdex DEXTRANOMER AND SODIUM HYALURONATE Solesta DIDANOSINE Videx Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ Sustiva EFAVIRENZ Sustiva ELTROMBOPAG Promacta EMTRICITABINE Emtriva EMTRICITABINE Emtriva EMTRICITABINE ENFOVIR; RILPIVIRINE Complera ENFURINE Surson ENFOVER SUSTIVAL SURSON ENFORMER SURSON ENFORMER SURSON ENFORMER SURSON ENFORMER SURSON ENFORMER SURSON ENFORMER SURSON ENTOR SURSON ENTER SURSON ENTOR SURSO		
CYSTEAMINE CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CytoGam  DALFAMPRIDINE Ampyra  DARBEPOETIN ALFA Aranesp DARUNAVIR DEFERASIROX DEFERASIROX DEGARELIX Firmagon DELAVIRDINE DENOSUMAB Prolia, Xgeva DESFEROXAMINE DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DONASE ALFA DIDANOSINE DONASE ALFA EULIZUMAB EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE EMTRICITABINE ENTECAVIR EPOPEROSTEROL ENTEROFOVIR ENTEROFOVIR; RILPIVIRINE ENTECAVIR ENTEROFOVIR ENTECAVIR ENTE	CRIZOTINIB	Xalkori
CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) DALFAMPRIDINE ARBEPOETIN ALFA Aranesp DARBEPOETIN ALFA Aranesp DARUNAVIR Prezista DASATINIB Sprycel DEFERASIROX Esjade DEGARELIX DEGARELIX DEGARELIX DEGARELIX DEGARELIX DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DESTERONOME Ozurdex DEXAMETHASONE OZURDEX DEXAMETHASONE OZURDEX DIDANOSINE DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ; TENOFOVIR; EMTRICITABINE EFAVIRENZ; TENOFOVIR; EMTRICITABINE EMTRICITABINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTECAVIR ENZE ENZELUT ALFA PPOPROSTENOL ENZELUT HIPORONI ENZELOR ENZELUT ALFA PPOCRIT, Epogen EPOPROSTENOL ERIORIUS ETANEROE EVEROLIMUS Afinitor, Zortress EACTOR IX COMPLEX	CYCLOSPORINE	Gengraf, Sandimmune, Neoral
(HUMAN)       CytoGam         DALFAMPRIDINE       Ampyra         DARBEPOETIN ALFA       Aranesp         DARUNAVIR       Prezista         DASATINIB       Sprycel         DEFERASIROX       Exjade         DEFERASIROX       Exjade         DEGARELIX       Firmagon         DELAVIRDINE       Rescriptor         DENOSUMAB       Prolia, Xgeva         DESFEROXAMINE       Desferal         DEXAMETHASONE       Ozurdex         DEXAMETHASONE       Ozurdex         DEXTRANOMER AND SODIUM HYALURONATE       Solesta         DIDANOSINE       Videx, Videx EC         DORNASE ALFA       Pulmozyme         ECULIZUMAB       Soliris         EFAVIRENZ       Sustiva         EFAVIRENZ       Sustiva         EFAVIRENZ       Sustiva         EFAVIRENZ       Sustiva         EFAVIRENZ       Emtriva         EMTRICITABINE       Atripla         EMTRICITABINE       Emtriva         EMTRICITABINE       Complera         ENTEURITIDE       Fuzeon         ENTECAVIR       Baraclude         ENTECAVIR       Baraclude         ENZALUTAMIDE       Xtandi     <		Cystagon
DARBEPOETIN ALFA  DARUNAVIR  DARUNAVIR  Prezista  DASATINIB  Sprycel  DEFERASIROX  DEGARELIX  Firmagon  DELAVIRDINE  Rescriptor  DENOSUMAB  Prolia, Xgeva  DESFEROXAMINE  DEXAMETHASONE  DEXTRANOMER AND SODIUM HYALURONATE  DIDANOSINE  DORNASE ALFA  Pulmozyme  ECULIZUMAB  Soliris  EFAVIRENZ; TENOFOVIR; EMTRICITABINE  ELTROMBOPAG  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  ENTRICITABINE; TENOFOVIR; RILPIVIRINE  ENTELOYING  ENTELOYING  ENTELOYING  POPOROSTENOL  EPOPROSTENOL  EPOPROSTENOL  ETANEROE  EVEROLIMUS  Afinitor, Zortress  EBAUIN, Bebulin VH		CytoGam
DARUNAVIR DASATINIB DASATINIB Sprycel DEFERASIROX Exjade DEGARELIX Firmagon DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DESFEROXAMINE DEXAMETHASONE OZURDEX DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG Promacta EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE COMPLET ENFUVIRTIDE ENFUCAVIR ENZELUTAMIDE ENTECAVIR ENZELUTAMIDE ENTECAVIR ENZELUTAMIDE ENTECAVIR EPOPROSTENOL FIOLAN, Veletri ERLOTINIB Tarceva ETANERCEPT Enbrel ETONOGESTREL Implanon, Nexplanon ETRAVIRINE EVEROLIMUS FACTOR IX COMPLEX BEBUIN, Bebulin VH	DALFAMPRIDINE	Ampyra
DASATINIB DEFERASIROX Exjade DEFERASIROX Exjade DEGARELIX Firmagon DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESTEROXAMINE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ: TENOFOVIR; EMTRICITABINE ELTROMBOPAG Promacta EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTRICITABINE; TENOFOVIR; RILPIVIRINE ENTRICITABINE; TENOFOVIR; RILPIVIRINE ENTECAVIR ENTECAVIR ENTECAVIR EPOETIN ALFA PROCRITE EPOETIN ALFA PROCRITE EPOPROSTENOL EINDANON ETRAVIRINE ETRONOR ETRAVIRINE ETRONOR ETRAVIRINE ETRONOR ETRAVIRINE ETRONOR ENDEL ENDEL ETRONOR EXPIRED ENDEL ETRONOR EXPIRED ENDEL ETRONOR ENDEL ETRONOR EXPIRED ENDEL ETRONOR ENDEL ETRONOR EXPIRED ENDEL ETRONOR ENDEL ETRONOR ENDEL ETRONOR EXPIRED ENDEL ETRONOR ENDEL ETRONO	DARBEPOETIN ALFA	Aranesp
DEFERASIROX DEGARELIX Firmagon DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE, TENOFOVIR; RILPIVIRINE ENTRICITABINE, TENOFOVIR; RILPIVIRINE ENTRICITABINE, TENOFOVIR; RILPIVIRINE ENTECAVIR E	DARUNAVIR	Prezista
DEGARELIX DELAVIRDINE Rescriptor DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DEXAMETHASONE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ Sustiva EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE EMTRICITABINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTECAVIR ENTONIO ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR	DASATINIB	Sprycel
DELAVIRDINE DENOSUMAB Prolia, Xgeva DESFEROXAMINE DESFEROXAMINE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ EFAVIRENZ EFAVIRENZ EFAVIRENZ ETAUROPOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTECAVIR ENTECAVI	DEFERASIROX	Exjade
DENOSUMAB DESFEROXAMINE DESFEROXAMINE DESFEROXAMINE DEXAMETHASONE Ozurdex DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC  DORNASE ALFA Pulmozyme ECULIZUMAB ECULIZUMAB Soliris EFAVIRENZ Sustiva EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG Promacta EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENFUVIRTIDE ENFUVIRTIDE ENTECAVIR ENZALUTAMIDE ENZALUTAMIDE EPOPROSTENOL FIOLAN, Veletri ERLOTINIB Tarceva ETANERCEPT EINDROMEN ENTELOR ENDROMEN ENTELOR ENTELOR ENDROMEN EN	DEGARELIX	Firmagon
DESFEROXAMINE DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ Sustiva EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE EMTRICITABINE EMTRICITABINE; TENOFOVIR; RILLPIVIRINE EMTRICITABINE; TENOFOVIR; RILLPIVIRINE Complera ENFUVIRTIDE ENTECAVIR ENTECAVIR EPOPROSTENOL EPOPROSTENOL ETANERCEPT ENDORGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS FACTOR IX COMPLEX Bebulin, Bebulin VH	DELAVIRDINE	Rescriptor
DEXAMETHASONE DEXTRANOMER AND SODIUM HYALURONATE DIDANOSINE Videx, Videx EC DORNASE ALFA Pulmozyme ECULIZUMAB Soliris EFAVIRENZ EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG EMTRICITABINE EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENTRICITABINE; TENOFOVIR ENTECAVIR ENTECAVIR ENTECAVIR ENTECAVIR ENZALUTAMIDE ENZALUTAMIDE EPOPROSTENOL EPOPROSTENOL ERLOTINIB ETANERCEPT ETONOGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS FACTOR IX COMPLEX	DENOSUMAB	Prolia, Xgeva
DEXTRANOMER AND SODIUM HYALURONATE  DIDANOSINE  Videx, Videx EC  Videx, Videx EC  Pulmozyme  ECULIZUMAB  ECULIZUMAB  EFAVIRENZ  EFAVIRENZ  EFAVIRENZ; TENOFOVIR; EMTRICITABINE  ELTROMBOPAG  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  ENTRICITABINE; TENOFOVIR  ENTRICITABINE; TENOFOVIR; RILPIVIRINE  ENFUVIRTIDE  ENFUVIRTIDE  ENZALUTAMIDE  ENZALUTAMIDE  ENZALUTAMIDE  EPOPROSTENOL  EPOPROSTENOL  ERLOTINIB  ETANERCEPT  ENDRE  ENDRE  ETANERCEPT  Enbrel  ETONOGESTREL  Implanon, Nexplanon  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  Bebulin, Bebulin VH	DESFEROXAMINE	Desferal
DIDANOSINE  DORNASE ALFA  Pulmozyme  ECULIZUMAB  Soliris  EFAVIRENZ  EFAVIRENZ  Sustiva  Atripla  ELTROMBOPAG  Promacta  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  ENFUVIRTIDE  ENTECAVIR  ENZALUTAMIDE  ENZALUTAMIDE  EPOPROSTENOL  EPOPROSTENOL  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  EVEROLIMUS  FACTOR IX COMPLEX  Bebulin, Bebulin VH	DEXAMETHASONE	Ozurdex
DORNASE ALFA  ECULIZUMAB  Soliris  EFAVIRENZ  Sustiva  EFAVIRENZ; TENOFOVIR; EMTRICITABINE  ELTROMBOPAG  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  ENTECAVIR  ENTECAVIR  ENTECAVIR  ENZALUTAMIDE  ENZALUTAMIDE  EPOPROSTENOL  EPOPROSTENOL  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  EVEROLIMUS  FACTOR IX COMPLEX  Bebulin, Bebulin VH	DEXTRANOMER AND SODIUM HYALURONATE	Solesta
ECULIZUMAB  EFAVIRENZ  EFAVIRENZ; TENOFOVIR; EMTRICITABINE  ELTROMBOPAG  ENTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  ENTRICITABINE; TENOFOVIR; RILPIVIRINE  ENFUVIRTIDE  ENFUVIRTIDE  ENTECAVIR  ENZALUTAMIDE  ENZALUTAMIDE  EPOPROSTENOL  EPOPROSTENOL  ERLOTINIB  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  EVEROLIMUS  FACTOR IX COMPLEX  Sustiva  Atripla  Atripla  Fruvada  Emtriva  Fuevon  Fuevon  Floan, Veletri  Flolan, Veletri  Implanon, Nexplanon  Intelence  EVEROLIMUS  Afinitor, Zortress  FACTOR IX COMPLEX	DIDANOSINE	Videx, Videx EC
EFAVIRENZ EFAVIRENZ; TENOFOVIR; EMTRICITABINE ELTROMBOPAG Promacta EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENFUVIRTIDE ENFUVIRTIDE ENTECAVIR Baraclude ENZALUTAMIDE ENZALUTAMIDE EPOETIN ALFA Procrit, Epogen EPOPROSTENOL Flolan, Veletri ERLOTINIB ETANERCEPT Enbrel ETONOGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS FACTOR IX COMPLEX  Bebulin, Bebulin VH	DORNASE ALFA	Pulmozyme
EFAVIRENZ; TENOFOVIR; EMTRICITABINE  ELTROMBOPAG  EMTRICITABINE  EMTRICITABINE  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  ENTECAVIR  ENTECAVIR  ENTECAVIR  ENZALUTAMIDE  ENZALUTAMIDE  EPOETIN ALFA  EPOPROSTENOL  ERLOTINIB  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  ETRAVIRINE  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  EATINA  Promacta  Emtriva  Truvada  Complera  Fuzeon  Fuzeon  Baraclude  Xtandi  Fuzeon  Flolan, Veletri  Tarceva  ETANERCEPT  Enbrel  Implanon, Nexplanon  ETRAVIRINE  Bebulin, Bebulin VH	ECULIZUMAB	Soliris
ELTROMBOPAG Promacta  EMTRICITABINE  EMTRICITABINE; TENOFOVIR  EMTRICITABINE; TENOFOVIR; RILPIVIRINE  ENFUVIRTIDE  ENFUVIRTIDE  ENTECAVIR  Baraclude  ENZALUTAMIDE  ENZALUTAMIDE  EPOETIN ALFA  Procrit, Epogen  EPOPROSTENOL  Flolan, Veletri  ERLOTINIB  Tarceva  ETANERCEPT  Enbrel  ETONOGESTREL  Implanon, Nexplanon  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  Bebulin, Bebulin VH	EFAVIRENZ	Sustiva
EMTRICITABINE EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE EMTRICITABINE; TENOFOVIR; RILPIVIRINE ENFUVIRTIDE ENTECAVIR ENTECAVIR Baraclude ENZALUTAMIDE ENZALUTAMIDE EPOETIN ALFA Procrit, Epogen EPOPROSTENOL Flolan, Veletri ERLOTINIB Tarceva ETANERCEPT Enbrel ETONOGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS FACTOR IX COMPLEX  Bebulin, Bebulin VH	EFAVIRENZ; TENOFOVIR; EMTRICITABINE	Atripla
EMTRICITABINE; TENOFOVIR EMTRICITABINE; TENOFOVIR; RILPIVIRINE Complera  ENFUVIRTIDE Fuzeon  ENTECAVIR Baraclude  ENZALUTAMIDE Xtandi  EPOETIN ALFA Procrit, Epogen  EPOPROSTENOL Flolan, Veletri  ERLOTINIB Tarceva  ETANERCEPT Enbrel  ETONOGESTREL Implanon, Nexplanon  ETRAVIRINE Intelence  EVEROLIMUS FACTOR IX COMPLEX Bebulin, Bebulin VH	ELTROMBOPAG	Promacta
EMTRICITABINE; TENOFOVIR; RILPIVIRINE  ENFUVIRTIDE  ENTECAVIR  Baraclude  ENZALUTAMIDE  ENZALUTAMIDE  EPOETIN ALFA  Procrit, Epogen  EPOPROSTENOL  ERLOTINIB  Tarceva  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  ETONOGESTREL  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  Complera  Fuzeon  Fuzeon  Enarclude  Fuzeon  Flolan, Veletri  Tarceva  Enbrel  Implanon, Nexplanon  Intelence  Afinitor, Zortress  Bebulin, Bebulin VH	EMTRICITABINE	Emtriva
ENFUVIRTIDE  ENTECAVIR  Baraclude  ENZALUTAMIDE  ENZALUTAMIDE  EPOETIN ALFA  EPOPROSTENOL  ERLOTINIB  Tarceva  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  ETONOGESTREL  EVEROLIMUS  FACTOR IX COMPLEX  Fuzeon  Etarceu  Etarceu  Fuzeon  Fuzeon  Fuzeon  Fuzeon  Floan, Veletri  Tarceva  Enbrel  Implanon, Nexplanon  Intelence  Afinitor, Zortress  Bebulin, Bebulin VH	EMTRICITABINE; TENOFOVIR	Truvada
ENTECAVIR  ENZALUTAMIDE  Xtandi  EPOETIN ALFA  Procrit, Epogen  EPOPROSTENOL  Flolan, Veletri  ERLOTINIB  Tarceva  ETANERCEPT  Enbrel  ETONOGESTREL  Implanon, Nexplanon  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  Baraclude  Rancel  Baraclude  Intelemce  Flolan, Veletri  Implanon, Nexplanon  Intelence  Bebulin, Bebulin VH	EMTRICITABINE; TENOFOVIR; RILPIVIRINE	Complera
ENZALUTAMIDE  EPOETIN ALFA  Procrit, Epogen  EPOPROSTENOL  ERLOTINIB  Tarceva  ETANERCEPT  ETONOGESTREL  ETONOGESTREL  ETRAVIRINE  EVEROLIMUS  FACTOR IX COMPLEX  Xtandi  Xtandi  Xtandi  Erocrit, Epogen  Flolan, Veletri  Enbrel  Inarceva  Enbrel  Implanon, Nexplanon  Intelence  Bebulin, Bebulin VH	ENFUVIRTIDE	Fuzeon
EPOETIN ALFA EPOPROSTENOL ERLOTINIB Tarceva ETANERCEPT ETONOGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS FACTOR IX COMPLEX EPOPROSTENOL Floan, Veletri Flolan, Veletri Enbrel Inarceva Enbrel	ENTECAVIR	Baraclude
EPOPROSTENOL Flolan, Veletri  ERLOTINIB Tarceva  ETANERCEPT Enbrel  ETONOGESTREL Implanon, Nexplanon  ETRAVIRINE Intelence  EVEROLIMUS Afinitor, Zortress  FACTOR IX COMPLEX Bebulin, Bebulin VH	ENZALUTAMIDE	
ERLOTINIB Tarceva  ETANERCEPT Enbrel  ETONOGESTREL Implanon, Nexplanon  ETRAVIRINE Intelence  EVEROLIMUS Afinitor, Zortress  FACTOR IX COMPLEX Bebulin, Bebulin VH	EPOETIN ALFA	Procrit, Epogen
ERLOTINIB  ETANERCEPT  Enbrel  ETONOGESTREL  Implanon, Nexplanon  ETRAVIRINE  Intelence  EVEROLIMUS  FACTOR IX COMPLEX  ERLOTINIB  Enbrel  Implanon, Nexplanon  Intelence  Bebulin, Bebulin VH	EPOPROSTENOL	
ETONOGESTREL Implanon, Nexplanon ETRAVIRINE Intelence EVEROLIMUS Afinitor, Zortress FACTOR IX COMPLEX Bebulin, Bebulin VH	ERLOTINIB	
ETRAVIRINE Intelence  EVEROLIMUS Afinitor, Zortress  FACTOR IX COMPLEX Bebulin, Bebulin VH	ETANERCEPT	Enbrel
ETRAVIRINE Intelence EVEROLIMUS Afinitor, Zortress FACTOR IX COMPLEX Bebulin, Bebulin VH	ETONOGESTREL	Implanon, Nexplanon
EVEROLIMUS Afinitor, Zortress FACTOR IX COMPLEX Bebulin, Bebulin VH	ETRAVIRINE	•
FACTOR IX COMPLEX Bebulin, Bebulin VH		
FACTOR XIII CONCENTRATE (HUMAN) Corifact	FACTOR IX COMPLEX	Bebulin, Bebulin VH

FILGRASTIM	Neupogen
FINGOLIMOD	Gilenya
FLUOCINOLONE	Retisert
FOLLITROPIN ALFA/BETA	Follistim AQ, Gonal-F
FOSAMPRENAVIR	Lexiva
GALSULFASE	
	Naglazyme
GLATIRAMER ACETATE	Copaxone
GOLIMUMAB	Simponi
GOSERELIN	Zoladex
HEPATITIS B IMMUNE GLOBULIN (HUMAN)	Nabi-HB
HEPATITIS B IMMUNE GLOBULIN INTRAVENOUS(HUMAN)	HepaGam B
HEPATITIS IMMUNE GLOBULIN	HyperHEP B
HISTRELIN	Vantas, Supprelin LA
HYALURONATE	Hyalgan, Supartz, Euflexxa, Orthovisc
HYDROXYPROGESTERONE CAPROATE	Makena
HYLANG-f20	Synvisc, Synvisc One
ICATIBANT	Firazyr
IDURSULFASE	Elaprase
ILOPROST	Ventavis
IMATINIB	Gleevec
IMIGLUCERASE	Cerezyme
IMMUNE GLOBULIN (HUMAN)	GamaSTAN S/D, HyperRHO S/D, MICRhoGAM, RhoGam
IMMUNE GLOBULIN INFUSION (HUMAN)	Gammagard
IMMUNE GLOBULIN INJECTION (HUMAN), 10%	
CAPRYLATE/CHROMATOGRAPHY PURIFIED	Gamunex-C
	Flebogamma, Carimune NF,
IMMUNE GLOBULIN INTRAVENOUS (HUMAN)	Gammagard SD, Gammaplex
IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID	Privigen
IMMUNE GLOBULIN INTRAVENOUS, HUMAN 5%	Octagam
IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% LIQUID	Hizentra
INCOBOTULINUMTOXIN A	Xeomin
INDINAVIR	Crixivan
INFLIXIMAB	Remicade
INTERFERON BETA-1A/B	Avonex, Rebif, Betaseron, Extavia
INTERFERON GAMMA-1B	Actimmune
IVACAFTOR	Kalydeco
LAMIVUDINE	Epivir, Epivir-HBV
LAMIVUDINE; ZIDOVUDINE	Combivir
LAPATINIB	Tykerb
LARONIADASE	Aldurazyme
LENALIDOMIDE	Revlimid
LEUPROLIDE	Eligard, Lupron
PROT KONING	Linguiu, Lupion

LEVONORGESTREL	Mirena, Skyla
LOPINAVIR; RITONAVIR	Kaletra
LUTROPIN ALFA	Luveris
MARAVIROC	Selzentry
MECASERMIN RECOMBINANT	Increlex
MENOTROPINS (FSH;LH)	Menopur, Repronex
MYCOPHENOLATE MOFETIL	CellCept, Myfortic
NALTREXONE	Vivitrol
NATALIZUMAB NELEDIA VID	Tysabri
NELFINAVIR	Viracept
NEVIRAPINE	Viramune
NILOTINIB	Tasigna
OCTREOTIDE	Sandostatin, Sandostatin LAR
OMACETAXINE	Synribo
OMALIZUMAB	Xolair
OPRELVEKIN	Neumega
PALIVIZUMAB	Synagis
PAZOPANIB	Votrient
PEGAPTANIB	Macugen
PEGFILGRASTIM	Neulasta
PEGINTERFERON ALFA-2A	Pegasys, PegasysProclick
PEGINTERFERON ALFA-2B	Pegintron, PegintronRedipen, Sylantron
PEGLOTICASE	Krystexxa
PEGVISOMANT	Somavert
PLERIXAFOR	Mozobil
RALTEGRAVIR	Isentress
RANIBIZUMAB	Lucentis
REGORAFENIB	Stivarga
Rho(D) Immune Globulin Intravenous (Human)	WinRho SDF
Kilo(D) Illilliulle Globulli Illitavellous (Hulliali)	
RIBAVIRIN	Copegus, Ribasphere, Rebetol, Ribatab, Ribapak
RILONACEPT	Arcalyst
RILPIVIRINE	Edurant
RITONAVIR	Norvir
ROMIPLOSTIM	Nplate
RUXOLITINIB	Jakafi
SAPROPTERIN	Kuvan
SAQUINAVIR	Invirase
SARGRAMOSTIM	Leukine
SILDENAFIL	Revatio
SIROLIMUS	Rapamune
	- tap annother

	Humatrope, Nutropin, Omnitrope,
	Saizen, Tev-Tropin, Genotropin,
SOMATROPIN RECOMBINANT	Serostim
SORAFENIB	Nexavar
STAVUDINE	Zerit
SUNITINIB	Sutent
TACROLIMUS	Prograf
TADALAFIL	Adcirca
TELBIVUDINE	T yzeka
TEMOZOLOMIDE	Temodar
TENOFOVIR	Viread
TERIFLUNOMIDE	Aubagio
TERIPARATIDE RECOMBINANT HUMAN	Forteo
TESAMORELIN	Egrifta
TETRABENAZINE	Xenazine
THALIDOMIDE	Thalomid
THYROTROPIN ALFA	Thyrogen
TIPRANAVIR	Aptivus
TOBRAMYCIN	Tobi
TOCILIZUMAB	Actemra
TOFACITINIB	Xeljanz
TOPOTECAN	Hycamtin
TREPROSTINIL	Remodulin, Tyvaso
TRIPTORELIN	Trelstar, Trelstar Depot
UROFOLLITROPIN	Bravelle
USTEKINUMAB	Stelara
VELAGLUCERASE ALFA	VPRIV
VEMURAFENIB	Zelboraf
VERTEPORFIN	Visudyne
VIGABATRIN	Sabril
VISMODEGIB	Erivedge
VORINOSTAT	Zolinza
ZIDOVUDINE	Retrovir
ZOLEDRONIC ACID	Reclast, Zometa

THESE QUESTIONS ARE ATTACHED FOR YOUR INFORMATION ONLY. RESPONSES TO THESE QUESTIONS SHOULD BE PROVIDED THROUGH THE ONLINE SURVEY.

## Attachment IX Online Survey Questions

# U.S. Office of Personnel Management 2013 Technical Guidance

As the 2013 Technical Guidance mentioned, OPM is implementing a new survey tool as part of this year's data collection for topics outlined in the Call Letter. The survey you are about to complete will allow you to enter and submit your answers electronically. You will have the opportunity to provide more detailed information and explanations in your proposal. If you have any questions while you are completing the survey, please contact your contract specialist.

<u>Please note</u>: You should have received an email from your contract specialist with a link(s) for each unique <u>contract</u>. If applicable, please make sure you complete a <u>separate</u> survey for <u>every</u> contract. We appreciate your effort and cooperation and look forward to working with you throughout the next plan year.

(End of Page 1)

Please fill in the blank for each line below:
Contract Number:
Plan Name:
Two Digit Carrier Code(s):
Contract Holders in the Plan as of March 31, 2013:
Covered Lives in the Plan as of March 31, 2013:
(End of Page 2)

### Section I: Prescription Drugs

A pharmacy growth rate trend includes:

>Inflation – cost of drugs per member per year

>Utilization – number of drugs used per member per year

>Mix – market basket of drugs dispensed and reimbursed

## drug trend for: 2012 (actual) please respond N/A if you were not in FEHB in 2012: 2013 (projected): \_\_\_\_\_ 2014 (projected): \_\_\_\_\_ If your pharmacy growth rate trend is projected to be higher than 8% for 2014, what actions will you take to lower it? (Please select all that apply) □ NA. Growth rate is lower than 8% □ Add/modify tiers ☐ Change cost sharing structure ☐ Add specialty pharmacy ☐ Add or expand step therapy ☐ Add or expand prior authorization ☐ Add or expand quantity limits for new specialty drug prescriptions ☐ Offer member educational campaign ☐ Offer 90-day retail program ☐ Change or add mail order benefits ☐ Offer incentive programs ☐ Offer Medication Therapy Management programs □ Narrow pharmacy networks or add preferred pharmacy network ☐ Develop an EGWP strategy ☐ Integrate specialty drugs dispensed in physician offices with PBM ☐ Other (please explain in your proposal)

Based on the above definition of pharmacy growth rate trend, please provide your overall

#### **Section I: Prescription Drugs-** continued

Generic Dispensing Rate (GDR) is defined as the percentage of total prescriptions filled with generic drugs. The denominator is the total number of prescriptions dispensed during the period and the numerator is the total number of prescriptions in the denominator that are dispensed as generics.

(End of Page 3)

Based on the above definition of GDR, please provide your GDR for:
2012 (actual) please respond N/A if you were not in FEHB in 2012:
2013 (projected):
2014 (projected):
If your projected GDR for 2014 is below the goal of 80%, what actions will you take to reach it? ( <i>Please select all that apply</i> )
□NA, GDR for 2014 is below 80%
□Add/modify tiers
□Change cost sharing structure
□Add or expand step therapy
□Add or expand prior authorization
□Offer member educational campaign
□Offer incentive programs
□Narrow or add preferred pharmacy networks
□Offer 90-day retail program
□Change or add mail order benefits
□Other (please explain in your proposal)
(End of Page 4)
Section I: Prescription Drugs - continued
OPM has developed a list ( <a href="www.opm.gov">www.opm.gov</a> ) of specialty drugs to use in your calculation of specialty drug trend. Using the list provided, what is your specialty drug trend for:
2012 (actual) please respond N/A if you were not in FEHB in 2012:
2013 (projected):
2014 (projected):
If your projected specialty drug trend for 2014 is above OPM's goal of 22%, what actions will you take to reduce it? ( <i>Please select all that apply</i> )
□NA projected specialty trend is less than 22%

□Add/modify tiers
□Change cost sharing structure
□Add specialty pharmacy
□Add or expand step therapy
□Add or expand prior authorization
□Add or expand quantity limits for new specialty drug prescriptions
□Offer member educational campaign
□Offer 90-day retail program
□Change or add mail order benefits
□Offer Medication Therapy Management programs
□Integrate specialty drugs dispensed in physician offices with PBM
□Other (please explain in your proposal)
Oncology drugs and therapeutics are commonly reimbursed on the medical side of the benefit and may not be included in your specialty drug program. You may, however, have special approaches to assess the appropriate use of these drugs. ( <i>Please select all that apply</i> )
□Clinical pathway or guideline program
□Decision support tools
□Outlier analysis
□Expert review
□Pre-authorization
□Other (please explain in your proposal)
(End of Page 5)
Section I: Prescription Drugs - continued
What drug utilization management edits or programs do you currently have to incentivize the use of clinically effective medications at low costs? (Please select all that apply)
□Step therapy
□Prior authorization

□Quantity Limits
□Adherence Programs
□Medication Management Programs
□Other (please specify in your proposal)
□None
In 2014, which areas will you use to increase incentives to use clinically effective, safe and low cost medications? (Please select all that apply)
□Step therapy
□Prior authorization
□Quantity Limits
□Adherence Programs
□Medication Management Programs
□Other (please specify in your proposal)
□None
(End of Page 6)
Section I: Prescription Drugs - continued
For 2013, what percentage of maintenance medications are provided through:
Retail pharmacy:
Mail service pharmacy:
Specialty pharmacy:
Please check the items below that your 2013 prescription drug benefit design contains. (Please select all that apply)
□Three tier benefit design
□Four tier benefit design
□More than four tier benefit design
□Copay cost sharing
□Coinsurance cost sharing

□Combination of copay and coinsurance
□ Designated specialty drug tier
□ Designated generic drug tier
□ Designated preferred brand drug tier
□Designated non-preferred brand drug tier
Please check the items below that your proposed 2014 prescription drug benefit design will contain.(Please select all that apply)
□Three tier benefit design
□Four tier benefit design
□More than four tier benefit design
□Copay cost sharing
□Coinsurance cost sharing
□Combination of copay and coinsurance
□ Designated specialty drug tier
□ Designated generic drug tier
□ Designated preferred brand drug tier
(End of Page 7)
Section II: Wellness and Preventive Care
All FEHB Program carriers must offer a health risk assessment (HRA). Our goal is to increase member participation significantly in 2014.
Participation rate is defined as the percentage of covered adults (members age 18 or above) completing the health risk assessment.
Estimate your plan's HRA participation rate for 2013:
Project your FEHB participation rate goal for 2014:
What is the reference standard for your plan's HRA? (Please select all that apply)
□National Committee on Quality Assurance
□Utilization Review and Accreditation Commission

□HERO Best Practice Scorecard
□Centers for Disease Control and Prevention
□Other (Please specify in your proposal)
(End of Page 8)
Section II: Wellness and Preventive Care - continued
Which incentives do you currently use to encourage HRA completion? (Please select all that apply)
□Member incentive
□Provider incentive
□Other (please specify in your proposal)
□None
Which additional incentives are you proposing for 2014 to increase HRA completion rates? (Please select all that apply)
□Member incentive
□ Provider incentive
□Other (please specify in your proposal)
□None
Note: Please specify the details of your plan to achieve your HRA participation goal in your rate/benefit proposal, including member outreach and incentives.
(End of Page 9)
Section II: Wellness and Preventive Care - continued
Carriers must begin offering biometric screening benefits for FEHB covered adults in 2014.
Please indicate which of the following elements will be included in your FEHB biometric screening benefits. (Please select all that apply)
□Body mass index (BMI)
□Waist circumference
□Lipid or cholesterol levels

□Blood pressure
□Tobacco use testing (cotinine, etc)
□Glucose or Hemoglobin A1c measurement
□Other (please specify in your proposal)
What is your participation goal for completion of biometric screenings (as a percent of FEHB covered adults):
For 2014:
Please indicate the venues in which you propose to provide biometric screening benefits:(Please select all that apply)
□Provider Office
□Retail clinic/urgent care
□Pharmacy
□Laboratory
□Workplace
□Fitness Center/Health Club
□Health Fair
□Other (please specify in your proposal)
Do you plan to contract with a vendor to provide biometric screenings?
☐ Yes (please describe the arrangement in your proposal)
□ No
Do you have a process in place to communicate biometric screening results to members' primary care physicians?
□ Yes
□ No
Note: Plans for biometric screening must be submitted with your rate/benefit proposal and describe the projected population and implementation costs, along with relevant incentives to achieve your participation goals.
(End of Page 10)

## Section III: Advancing Quality of Care

When your plan assesses network hospitals, which of the following performance measures do you evaluate? (Please select all that apply)
□Facility specific readmission rates
□CMS measures of hospital acquired conditions (www.medicare.gov/hospitalcompare)
□ Joint Commission Core Measures (http://www.jointcommission.org/core_measure_sets.aspx)
□Leapfrog measures of hospital quality and safety (www.leapfroggroup.org)
□Any measure of early elective obstetric delivery
□Other patient safety measures
□Other surgical checklists
□Other medication reconciliation
□Other fall prevention protocols
□Other, unspecified (please specify in your proposal)
(End of Page 11)
Section III: Advancing Quality of Care - continued  OPM requires FEHB plans that offer PCMH to utilize criteria that document enhanced access, management of patient populations, care management and planning, provision of self-care support, care coordination, and performance measurement.
Which of the following programs do you use to certify or recognize PCMH? (Please select all that apply)
□NCQA Patient Centered Medical Home Recognition—Levels 2 and 3
□The Joint Commission Primary Care Medical Home Certification
□URAC Patient Centered Health Care Home Certification
□ AAAHC Medical Home Certification
$\hfill \Box Alternative$ method (contract specialist will provide supplemental worksheet for submission of details)
How many FEHB covered lives are currently enrolled in a PCMH practice affiliated with your plan:

As of April 1, 2013:
How many FEHB covered lives are currently enrolled in a practice participating in the CMS Comprehensive Primary Care Initiative:
As of April 1, 2013:
What percentage of your plan's primary care providers serving FEHB members are certified or recognized as PCMH according to the criteria listed above:
As of April 1, 2013:
What is your goal for 2014:
(End of Page 12)
Section III: Advancing Quality of Care - continued
After considering the commonly overused tests and procedures highlighted in the Choosing Wisely Campaign, (the numbered elements are available for review and selection at <a href="www.opm.gov">www.opm.gov</a> ) please identify 3 tests or procedures by the coordinating number that your plan will focus on this year as part of your utilization management program. OPM will use this information to inform the selection of HEDIS measures reported by all plans in 2014.
Procedure #1
Procedure #2
Procedure #3
What percent of your plan's network providers have achieved <u>Stage 1</u> or <u>Stage 2</u> of the Meaningful Use of health information technology?
(End of Page 13)
Section IV: Coverage and Benefits: Applied Behavioral Analysis (ABA)
Does your service area include one or more states with an insurance mandate to cover ABA for children with autism?
□Yes >>>> Skip to Page 15: In states with a mandate to cover ABA services, do you offer ABA services in any of your non-FEHB health insurance products?
□No >>>> Skip to Page 17: Our research shows that CO, CT, NJ, SC, and VA have mandated ABA coverage; large populations of federal workers; and significant numbers of ABA providers. Do you operate in one of these states?

### (End of Page 14)

## Section IV: Coverage and Benefits: Applied Behavioral Analysis (ABA)- continued In states with a mandate to cover ABA services, do you offer ABA services in any of your non-FEHB health insurance products? □Yes >>>> Skip to Page 16: OPM encourages your plan to propose ABA coverage for FEHB members. □No >>>> Skip to Page 17: Our research shows that CO, CT, NJ, SC, and VA have mandated ABA coverage; large populations of federal workers; and significant numbers of ABA providers. Do you operate in one of these states? (End of Page 15) Section IV: Coverage and Benefits: Applied Behavioral Analysis (ABA)- continued OPM encourages your plan to propose ABA coverage for FEHB members. □ Plan already covers ABA for FEHB members □ Plan is proposing coverage for 2014 benefit year for FEHB members □ Plan projects an ability to propose coverage for FEHB members in (fill in the benefit year) (End of Page 16) Section IV: Coverage and Benefits: Applied Behavioral Analysis (ABA)- continued Our research shows that CO, CT, NJ, SC, and VA have mandated ABA coverage; large populations of federal workers; and significant numbers of ABA providers. Do you operate in one of these states? □Yes >>>> Skip to Page 18: Are you able to include ABA coverage for FEHB members in these states as part of your 2014 rate/benefit proposal? □No >>>> Skip to Page 19: For FEHB members who have obesity uncomplicated by other medical conditions, what is your plan's BMI threshold for bariatric surgery? (End of Page 17)

### Section IV: Coverage and Benefits: Applied Behavioral Analysis (ABA) - continued

Are you able to include ABA coverage for FEHB members in these states as part of your 2014 rate/benefit proposal? □Yes □No(please explain the primary reason in your rate/benefit proposal) (End of Page 18) Section V: Coverage and Benefits: Bariatric Surgery For FEHB members who have obesity uncomplicated by other medical conditions, what is your plan's BMI threshold for bariatric surgery? Please specify as kg/m2: \_\_\_\_\_ For FEHB members whose obesity is complicated by diabetes, what is your plan's BMI threshold for bariatric surgery? Please specify as kg/m2: \_\_\_\_\_ What is your required pre-surgical waiting period for bariatric surgical procedures? □<6 months □6-12 months □12-24 months □Longer than 24 months Do you direct FEHB members to bariatric surgical centers of excellence? □Yes □No Which bariatric surgical procedures are covered? (Please select all that apply) □Roux-en-Y gastric bypass □ Adjustable gastric banding ☐Sleeve gastrectomy □ Duodenal switch procedure

□Other malabsorptive procedure(s)

□Other restrictive procedure(s)
□Other combination procedure(s)
(End of Page 19)
Section VI: Medicare Population Pilots
Have you submitted a proposal for a pilot program to offer a sub-option for Medicare eligible annuitants as an alternate choice?
□ Yes
□ No
Note: Please provide detailed responses in your proposals.
(End of Page 20)
Section VII: Affordable Care Act (ACA) Compliance
In 2014, will you comply with the Affordable Care <u>Act requirements</u> for preventive services at no cost (65 total preventive services)?
□Yes
□No
In 2014, will you comply with the Affordable Care Act's limits for out-of-pocket maximums for non-grandfathered large group health plans in 2014?
□Yes
□No
(End of Page 21)
Section VIII: Geriatric Providers
Do you have a mechanism to identify providers with geriatric training or certification (including those PCPs with these qualifications) in your FEHBP directory?
□Yes
□No

As of April 1, 2013, how many FEHB members over the age of 65 do you have?				
Note: Please describe your mechanism in your proposal.				
(End of Page 22)				
Section IX: Affinity Products				
Do you offer individual policies for FEHB domestic partners?				
□Yes				
□No				
Do you offer short-term disability coverage for FEHB members?				
□Yes				
□No				
Do you list individual policies for domestic partners on your non-FEHB page?				
□Yes				
□No				
Do you list short-term disability coverage on your non-FEHB page?				
□Yes				
□No				
(End of Page 23)				
Section X: Brochure Cost Savings from Going Green Initiative				
Was 2013 your first year in FEHB?				
☐ Yes >>>> Skip to Page 25: Please estimate your brochure cost savings in 2012:				
□ No >>>> Skip to Page 26:				
(End of Page 24)				

Section X: Brochure Cost Savings from Going Green Initiative - continued

Please estimate your brochure cost savings in 2012:

Printing Savings (in U.S. dollars):
Shipping Savings (in U.S. dollars):
Postage Savings (in U.S. dollars):
Other savings (please specify the type in your proposal):
Total Savings (in U.S. dollars):
Please estimate your total brochure cost savings since the beginning of the Going Green Initiative in 2011:
Printing Savings (in U.S. dollars):
Shipping Savings (in U.S. dollars):
Postage Savings (in U.S. dollars):
Other savings (please specify the type in your proposal):
Total Savings in 2011 and 2012 (in U.S. dollars):
(End of Page 25)
You have reached the end of the electronic portion of the 2013 Technical Guidance. We recommend reviewing all of your answers before submitting the form. Once you click submit, you will not be able to go back and edit any answers. Please keep in mind, however, that you will have the opportunity to provide more details and information in your benefit proposal. Thank you for your time. The information you have provided will strongly contribute to the success of FEHB.
(End of Page 26)

# Attachment X 2014 Technical Guidance Submission Checklist

Topic/Attachment Number	In Proposal Yes/No/NA	Worksheet Completed Yes/No/NA	Online Survey Completed Yes/No/NA
FEHB Carrier Contracting Official (Attachment I)		1 65/1\0/1\A	N/A
Benefit Change Worksheet: worksheet for each change			N/A
(Attachment II)			
Benefit Clarification Worksheet: worksheet for each			N/A
clarification (Attachment III)			
Preparing Your 2014 Brochure (Attachment IV)			
Grandfathered Status Certification, if applicable			N/A
(AttachmentV)			
Pharmacy - Pharmacy Drug Trend (Attachment VI)			
Pharmacy - Dispensing Rate (Attachment VI)			
Pharmacy - Specialty (Attachment VI)			
Organ/Tissue Transplants Diagnoses: Tables 1, 2 & 3			N/A
(Attachment VII)			
Specialty Drug List (Attachment VIII)	N/A	N/A	N/A
Online Survey Questions (Attachment IX)	N/A	N/A	
Technical Guidance Submission Checklist (Attachment X)	N/A		N/A

Please return this checklist with your CY 2014 benefit and rate proposal